Comparison of Helicobacter pylori eradication rates between 7 and 14 days of tailored therapy according to clarithromycin resistance test: A randomized, multicenter, non‐inferiority study

克拉霉素 医学 内科学 幽门螺杆菌 养生 阿莫西林 意向治疗分析 甲硝唑 不利影响 雷贝拉唑 随机对照试验 胃肠病学 抗生素 生物 微生物学
作者
Kyoungwon Jung,Sam Ryong Jee,Moon Won Lee,Myeongseok Koh,Su Jin Kim,Jin Lee,Moo In Park
出处
期刊:Helicobacter [Wiley]
卷期号:29 (3)
标识
DOI:10.1111/hel.13084
摘要

Abstract Background Recently, a simple tailored therapy based on clarithromycin resistance has been implemented as Helicobacter pylori ( H. pylori ) eradication therapy. Nonetheless, despite the tailored therapy and frequent adverse events, studies on treatment period are lacking. This study aimed to compare the H. pylori eradication rates of 7‐day and 14‐day tailored therapy regimens according to clarithromycin resistance. Materials and Methods This multicenter, prospective, randomized, noninferiority trial enrolled H. pylori ‐positive patients who were randomly assigned to 7‐day and 14‐day regimen groups, depending on the presence or absence of clarithromycin resistance by 23S rRNA gene point mutations. Standard triple therapy (STT) (20 mg rabeprazole, 1 g amoxicillin, and 500 mg clarithromycin twice daily) or bismuth quadruple therapy (BQT) (20 mg rabeprazole twice daily, 500 mg metronidazole thrice daily, 120 mg bismuth four times daily, and 500 mg tetracycline four times daily) was assigned by clarithromycin resistance. Eradication rates and adverse events were evaluated. Results A total of 314 and 278 patients were included in the intention‐to‐treat (ITT) and per‐protocol (PP) analyses, respectively; however, 31 patients were lost to follow‐up, whereas five patients violated the protocol. Both the 7‐day and 14‐day regimens showed similar eradication rates in the ITT (7‐day vs. 14‐day: 78.3% vs. 78.3%, p > 0.99) and PP (87.9% vs. 89.1%, p = 0.851) analyses. Non‐inferiority was confirmed ( p < 0.025). A subgroup analysis according to clarithromycin resistance (clarithromycin resistance rate: 28.7%) revealed no significant difference in eradication rates between the 7‐day and 14‐day STT (90.0% vs. 90.1%, p > 0.99) and BQT (82.5% vs. 86.5%, p = 0.757). Furthermore, adverse events did not significantly differ between the two groups. Conclusions The 7‐day triple and quadruple therapy according to clarithromycin resistance showed similar eradication rates, as compared to the 14‐day therapy.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
zh关闭了zh文献求助
刚刚
1秒前
细腻慕儿完成签到 ,获得积分10
1秒前
XUNGEER11完成签到,获得积分10
1秒前
1秒前
2秒前
小圆发布了新的文献求助10
2秒前
lipeng完成签到,获得积分10
2秒前
hf完成签到,获得积分10
3秒前
3秒前
英姑应助余甘木采纳,获得10
3秒前
风趣的胜应助王玉采纳,获得10
3秒前
3秒前
我是老大应助wwz采纳,获得10
3秒前
勤奋的琳完成签到,获得积分10
4秒前
Tomice发布了新的文献求助10
4秒前
ding应助能能鹤采纳,获得10
5秒前
enen发布了新的文献求助10
5秒前
周周发布了新的文献求助10
5秒前
所所应助听枫采纳,获得10
5秒前
123完成签到,获得积分10
5秒前
香蕉觅云应助XUNGEER11采纳,获得10
6秒前
6秒前
扭扭车发布了新的文献求助10
6秒前
龙哥发布了新的文献求助10
7秒前
7秒前
洪亮完成签到,获得积分0
7秒前
8秒前
drfy123发布了新的文献求助10
8秒前
研友_VZG7GZ应助独特的苗条采纳,获得10
9秒前
9秒前
Little2发布了新的文献求助10
10秒前
盛夏之末应助太阳吖采纳,获得10
10秒前
星辰大海应助mrmrer采纳,获得10
10秒前
hhh完成签到,获得积分20
11秒前
逸鑫林完成签到 ,获得积分10
12秒前
大模型应助mirayq采纳,获得10
12秒前
12秒前
Ava应助21采纳,获得10
13秒前
13秒前
高分求助中
Ophthalmic Equipment Market by Devices(surgical: vitreorentinal,IOLs,OVDs,contact lens,RGP lens,backflush,diagnostic&monitoring:OCT,actorefractor,keratometer,tonometer,ophthalmoscpe,OVD), End User,Buying Criteria-Global Forecast to2029 2000
A new approach to the extrapolation of accelerated life test data 1000
Cognitive Neuroscience: The Biology of the Mind 1000
Cognitive Neuroscience: The Biology of the Mind (Sixth Edition) 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 588
Christian Women in Chinese Society: The Anglican Story 500
A Preliminary Study on Correlation Between Independent Components of Facial Thermal Images and Subjective Assessment of Chronic Stress 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3961269
求助须知:如何正确求助?哪些是违规求助? 3507536
关于积分的说明 11136688
捐赠科研通 3239991
什么是DOI,文献DOI怎么找? 1790625
邀请新用户注册赠送积分活动 872449
科研通“疑难数据库(出版商)”最低求助积分说明 803199